Industry Express | OPEN AI-grundlæggeren Sam Altman investerede 180 millioner dollars i Anti-aging Star up
In the pass decades days, the Open AI and the amazing founder behind AI application both captured attention world widely. But recently, as MIT Technology Review reported, the OpenAI CEO Sam Altman has turned out to be the investor that paid $180 million to get biotech startup Retro Biosciences off the ground.
Altman anti-aging teori, formning og investering
Motivated by his own idea of three biggest positive humans affairs of AI, energy, and anti-aging biotech, the investment to anti-aging area should date back to eight years ago. Altman told Tech Review that he became fascinated by “young blood” research, in which old mice have their fluids swapped out with fresher juice in 2015. It was through this burgeoning interest, and a conversation about a 2020 plasma mouse study, that he reportedly first expressed a desire to pursue anti-aging work. From those initial motivation, a business partnership blossomed. What’s more, Altman's have highlighted that his anti-aging regimen includes Prøver at spise sundt, motionere og sove nok. Han tog i bund og grund hele sin likvide nettoformue og investerede den i to virksomheder, hvoraf det ene hed Retro Biosciences.
Investeringen fra Sam Altman i denne livsforlængende startup er et positivt signal for udviklingen af anti-aging forretninger. Det viser, at der er en voksende interesse og støtte til forskning og udvikling inden for anti-aldring, og det kan bane vejen for, at andre investorer og virksomheder kan komme ind på området. På den anden side er det en vigtig milepæl i anti-aldringsindustrien. Den fremhæver potentialet i anti-aldringsteknologier til at forbedre menneskets levetid og livskvalitet.
Retro Bio anti-aging teori
Baseret på MIT Technology Review, Retro Biosciences har til formål at adressere de underliggende årsager til aldring ved at udvikle terapier, der retter sig mod cellulære og molekylære mekanismer. Den anvender banebrydende teknologier som genredigering, stamcelleterapi og kunstig intelligens til at udvikle interventioner, der kan bremse eller endda vende aldringsprocessen. Og det offentligt lanceret i april 2022, under ledelse af direktøren Joe Betts-LaCroix, another Y Combinator alum and health startup entrepreneur. At launch, the company had secured funding for an ambitious mission of Tilføjer 10 år til den sunde menneskelige levetid. Det annoncerede, at de havde rejst 180 millioner dollars i den indledende finansieringsrunde, som tilsyneladende kom i form af en fortrolig check fra Altman i 2021.
Bontac står på anti-aging punkter
Bontac-anti-aldringsteorien stammer fra David Sinclair, som er professor ved Institut for Genetik og meddirektør for Paul F. Glenn Center for Biology of Aging Research ved Harvard Medical School. Teknisk set fremhævede han effekterne af anti-aging for NMN (nicotinamidmononukleotid) set fra teoriens og eksperimenternes perspektiver, og Bontac har spillet en rolle for NMN-industrialiseringspraktikere.
NMN is a molecule that has gained attention for its potential anti-aging properties. It is a precursor to NAD+ (nicotinamide adenine dinucleotide), which is an essential coenzyme involved in many cellular processes, including energy metabolism and DNA repair. NMN's mechanism of action in anti-aging appears to be related to its ability to increase NAD+ levels and activate sirtuins, leading to improvements in cellular processes that decline with age.
Reference:
https://sinclair.hms.harvard.edu/people/david-sinclair
https://www.technologyreview.com/2023/03/08/1069523/sam-altman-investment-180-million-retro-biosciences-longevity-death/
